Clinical Trials - January 22, 2020
Medivir phase II study published in Annals of Internal Medicine
Medivir has announced that the phase II study of MIV-711 in patients with osteoarthritis has been published in the journal Annals of Internal Medicine. The title of the article is “Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis”, author; P.G Conaghan et al. In the same issue there is an editorial by J.N […]
Drug Development Pharma - January 20, 2020
Idogen’s cell technology advanced to large-scale production
Idogen has announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. Results from completed tests show that the technology platform can now generate functional cells in considerably larger volumes than previously possible, states the company. As the next step, Idogen now initiates the partnership with […]
Drug Development Pharma - January 16, 2020
New study shows Sigrid’s medical device prevents weight gain
Sigrid Therapeutics has announced the publication of a study in mice in the journal Nanomedicine demonstrating the enzyme-blocking effects of mesoporous silica particles (MSPs) introduced to the gut and the resulting effect on food efficiency and metabolic risk factors. “These results are very exciting and open up for new possibilities of SiPore15 to be used […]
Drug Development Pharma - October 2, 2019
FDA approval for Genmab’s Darzalex in combination with Bortezomib, Thalidomide and Dexamethasone
Genmab has announced that the U.S. Food and Drug Administration has approved the use of DARZALEX (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd) as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The supplemental Biologics License Application (sBLA) for this indication was submitted by […]
Agreement - September 4, 2019
Zealand Pharma and Boehringer Ingelheim initiate Phase 2 development of BI 456906
Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. Potential as […]
Drug Development Pharma - August 28, 2019
FDA grants Fast Track designation for AstraZeneca’s Farxiga
The US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD). The FDA’s Fast Track programme is designed to accelerate the development and review of new medicines […]
